LOS ANGELES ― Barry E. Gidal, PharmD, FAES has been elected to the American Epilepsy Society (AES) board of directors beginning at the conclusion of the Society's 2024 Annual Meeting in Los Angeles, Dec. 6-10, 2024. A medical and scientific society of more than 5,200 members, the AES is dedicated to advancing research and education for preventing, treating and curing epilepsy.
Dr. Barry E. Gidal is a distinguished professor of pharmacy and associate dean for faculty affairs at the University of Wisconsin, Madison. He also maintains an active clinical practice at the William S. Middleton Memorial Veterans’ Hospital Epilepsy Clinic, part of the Epilepsy Center of Excellence (ECoE).
Dr. Gidal earned a Doctor of Pharmacy degree from the University of Washington (UW), Seattle. He completed a clinical residency at UW Hospitals and remained at UW for a clinical pharmacokinetics fellowship in the Department of Pharmaceutics and Pharmacy Practice.
Dr. Gidal’s research interest is in adult epilepsy. His area of focus is in antiseizure medication pharmacokinetics, pharmacodynamics and drug interactions. Dr. Gidal has been a principal or co-investigator on multiple research studies. He has authored or co-authored numerous book chapters, and over 150 peer-reviewed articles in medical and scientific literature. Dr. Gidal currently serves on the editorial board for Epilepsy & Behavior and is an associate editor for Epilepsy & Behavior Reports and Epilepsia. He is co-editor of the medications section of Epilepsy.com and an associate editor for “Wyllie’s Treatment of Epilepsy.”
For more information, visit the American Epilepsy Society online at aesnet.org. Join the AES social conversation today by following @AmEpilepsySoc on X and use the hashtag #AES2024.